Are Analysts Bearish Valeant Pharmaceuticals International, Inc. (NYSE:VRX) After Last Week?

January 17, 2018 - By Adrian Mccoy

 Are Analysts Bearish Valeant Pharmaceuticals International, Inc. (NYSE:VRX) After Last Week?
Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.09, from 1.08 in 2017Q2. It dived, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million shares in 2017Q2 were reported.
Shanda Asset Holding Limited holds 1.34% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 700,000 shares. 1.43M are owned by Blackrock. Carl Domino owns 0.38% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 22,000 shares. The United Kingdom-based Pictet Asset Mngmt Ltd has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). First Republic accumulated 401,002 shares. 599 are held by Valley Natl Advisers. Pnc Fin Services Grp Inc accumulated 8,506 shares. Bb&T Limited Liability reported 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Grp Inc One Trading Lp, a Illinois-based fund reported 1.98 million shares. Fosun Interest reported 2.54% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 1,714 were accumulated by Sei Investments. Conning reported 340,679 shares or 0.17% of all its holdings. 56 were reported by First Manhattan Company. 1.58 million are owned by Legal And General Plc. Comerica National Bank has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 5 Sell and 16 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 149 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Wednesday, June 28. Cantor Fitzgerald has “Buy” rating and $2300 target. Guggenheim maintained the shares of VRX in report on Friday, November 6 with “Buy” rating. Piper Jaffray downgraded the stock to “Underweight” rating in Tuesday, March 15 report. The stock has “Sector Outperform” rating by Scotia Capital on Wednesday, October 14. Wells Fargo initiated the shares of VRX in report on Friday, February 19 with “Underperform” rating. The firm earned “Outperform” rating on Monday, December 14 by RBC Capital Markets. As per Wednesday, May 10, the company rating was maintained by RBC Capital Markets. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Sell” rating by Mizuho on Tuesday, November 7. The rating was maintained by JP Morgan with “Overweight” on Wednesday, March 16. The firm earned “Hold” rating on Monday, November 14 by Deutsche Bank. Below is a list of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) latest ratings and price target changes.

16/01/2018 Broker: H.C. Wainwright Rating: Hold Maintain
15/12/2017 Broker: Mizuho Rating: Underperform Old Target: $7.00 New Target: $10.00 Maintain
14/12/2017 Broker: J.P. Morgan Rating: Sell Downgrade
14/12/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
04/12/2017 Broker: BTIG Research Rating: Hold Maintain
13/11/2017 Broker: Inc. Rating: Bmo Capital New Target: $16 17
09/11/2017 Broker: BTIG Research Rating: Hold Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Hold New Target: $17.0 Maintain
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0 Maintain
07/11/2017 Broker: Mizuho Rating: Sell New Target: $7.0 Maintain

The stock decreased 3.61% or $0.86 during the last trading session, reaching $22.98. About 14.89M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since January 17, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $8.00 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 5.86 P/E ratio. Diversified Products.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Seekingalpha.com which released: “Valeant: Positive Catalysts Kick Off New Year” on January 04, 2018, also Investorplace.com with their article: “Be Extremely Careful With Valeant Pharmaceuticals Intl Inc Stock Price” published on December 21, 2017, Prnewswire.com published: “Valeant Pays Down $300 Million Of Senior Secured Term Loans” on January 03, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Seekingalpha.com and their article: “Update: Valeant’s Turnaround Progressing To Midgame” published on January 08, 2018 as well as Reuters.com‘s news article titled: “Ex-Valeant CEO must arbitrate case over unpaid stock: US judge” with publication date: December 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.